Spyre Doses First Patient in Phase 2 Rheumatic Disease Trial
Spyre Therapeutics has dosed the first patient in SKYWAY, a randomized, placebo-controlled Phase 2 basket trial of SPY072, an...
Jon Napitupulu
What Happened In The Efzofitimod Sarcoidosis Phase 3 Study
Efzofitimod missed the primary endpoint in the Phase 3 EFZO-FIT study, reducing mean daily oral corticosteroid dose at week...
Valuable Insight: Breast Cancer ADC Market & Trials to 2030
More than 100 antibody-drug conjugates (ADCs) targeting breast cancer are in clinical development, with use expanding from late-line metastatic...
New Long-Term ALXN1840 Neurological Data for Wilson Disease
Statistically significant neurological improvement on the Unified Wilson Disease Rating Scale Parts II and III was sustained for up...
Lexicon Submits Additional Zynquista® Data to FDA for Diabetes
Lexicon submitted additional clinical data to the FDA from three ongoing investigator-initiated studies of sotagliflozin to address the agency’s...
Pasithea NF1 Trial Advances to Cohort 2 on Positive Safety
No dose-limiting toxicities were observed in the first three patients treated with PAS-004 at the initial dose in Pasithea’s...
CRISPR to Unveil New Heart Data at AHA Scientific Sessions
CRISPR Therapeutics will debut first-in-human Phase 1 data for its in vivo CRISPR/Cas9 therapy CTX310, which targets ANGPTL3 for...
Eye-opening Study: Patient Confusion Over Health Care Titles
Only 9% of more than 1,000 California adults correctly matched a healthcare practitioner’s title to the level of training...
Belite Bio Completes Phase 3 Stargardt Disease Trial
Belite Bio has completed the last subject visit in its pivotal Phase 3 DRAGON trial of tinlarebant for adolescent...
Successful Phase 1 Study for New Alzheimer’s Drug GAL-101
Galimedix reported completion of a Phase 1 study of oral GAL-101 in more than 100 healthy volunteers, showing the...